Table 1.
Patient demographics, molecular pathology, and treatment history.
| Consented patients (N) | 149 |
| Treated patients [N (% of consented patients)] | 83 (55.7%) |
| Patients with ≥1 matched treatment [N (% of consented patients)] | 73 (49.0%) |
| Patients with no matched treatments administered [N (% of consented patients)] | 10 (6.7%) |
| Age1 (Median, 95% CI, Range) | 62 (59–65, 21–86) |
| Gender1 [N (%)] | |
| Women | 55 (66.3%) |
| Men | 28 (33.7%) |
| Ethnicity1 [N (%)] | |
| Caucasian | 67 (80.7%) |
| Asian | 4 (4.8%) |
| African American | 1 (1.2%) |
| Other or unknown | 11 (13.3%) |
| Tumor type1 [N (%)] | |
| Gastrointestinal & hepatopancreatobiliary | 35 (42.2%) |
| Gynecologic | 14 (16.9%) |
| Breast | 12 (14.5%) |
| Central nervous system (CNS) | 6 (7.2%) |
| Genitourinary | 3 (3.6%) |
| Head and neck | 3 (3.6%) |
| Lung | 3 (3.6%) |
| Other2 | 7 (8.4%) |
| Number of total genomic alterations1 (Median, Range; VUS excluded) | 5 (1–19) |
| Number of administered drugs1 (Median, Range) | 2 (1–5) |
| Median number of prior therapies in the metastatic setting1 (Median, IQR) | 2 (1–3) |
1
Parameters shown are for the 83 treated patients (N=83).
2
Other included liposarcoma (N=2); carcinoma of the skin, neuroendocrine carcinoma, fibromyxoid sarcoma, bone marrow multiple myeloma, and paraganglioma (N=1 each).
Abbreviations: CI = Confidence Interval; IQR = interquartile range: N=number; VUS = variant of unknown significance.